Polymer Coated Ceria Nanoparticles for Selective Cytoprotection (CIP) by Perez Figueroa, J. Manuel et al.
University of Central Florida 
STARS 
UCF Patents Technology Transfer 
9-1-2015 
Polymer Coated Ceria Nanoparticles for Selective Cytoprotection 
(CIP) 
J. Manuel Perez Figueroa 
University of Central Florida 
Atul Asati 
University of Central Florida 
Charalambos Kaittanis 
University of Central Florida 
Sudip Nath 
University of Central Florida 
Find similar works at: https://stars.library.ucf.edu/patents 
University of Central Florida Libraries http://library.ucf.edu 
This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for 
inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact 
STARS@ucf.edu. 
Recommended Citation 
Perez Figueroa, J. Manuel; Asati, Atul; Kaittanis, Charalambos; and Nath, Sudip, "Polymer Coated Ceria 
Nanoparticles for Selective Cytoprotection (CIP)" (2015). UCF Patents. 468. 
https://stars.library.ucf.edu/patents/468 
c12) United States Patent 
Perez et al. 
(54) POLYMER COATED CERIA 
NANOPARTICLES FOR SELECTIVE 
CYTOPROTECTION 
(75) Inventors: Jesus Manuel Perez, Orlando, FL (US); 
AtulAsati, Orlando, FL (US); Sudip 
Nath, Orlando, FL (US); Charalambos 
Kaittanis, Oviedo, FL (US) 
(73) Assignee: University of Central Florida Research 
Foundation, Inc., Orlando, FL (US) 
( *) Notice: Subject to any disclaimer, the term ofthis 
patent is extended or adjusted under 35 
U.S.C. 154(b) by 1241 days. 
This patent is subject to a terminal dis-
claimer. 
(21) Appl. No.: 12/169,179 
(22) Filed: Jul. 8, 2008 
Related U.S. Application Data 
(63) Continuation-in-part of application No. 11/965,343, 
filed on Dec. 27, 2007. 
(60) Provisional application No. 60/949,953, filed on Jul. 
16, 2007. 








CPC ........................................ AOlN 1102 (2013.01) 
( 58) Field of Classification Search 
IPC .......... AOlN 1/02,1/0226; A61K 33/00, 9/5161 
See application file for complete search history. 
(56) References Cited 


























2/1992 Deppe et al. 
5/1995 Johnson et al. 
111996 Caplan et al. 
611999 Boussouira 
10/ 1999 Boussouira 
3/2000 Lin et al. 
8/2000 Boussouira 
10/2000 Borglum et al. 
1112001 N'Guyen 
12/2001 Bass et al. 





12/2002 Bass et al. 
7/2003 Schmid-Schoenbein et al. 
1112003 Bass et al. 
112005 Bass et al. 
512005 Shashoua 
10/2005 Lee et al ......................... 216/89 
212006 Hsei et al. 
712006 Rapaport et al. 
1112006 Chan 
9/2007 Shimp et al. 
I lllll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111 
US009119391Bl 
(10) Patent No.: 
(45) Date of Patent: 
US 9,119,391 Bl 
*Sep.1,2015 
7,347,987 B2 3/2008 McGinnis et al. 
7,431,758 B2 10/2008 Ota et al. 
7,442,686 B2 10/2008 Lasko et al. 
7,471,706 B2 12/2008 Bass et al. 
7,504,356 Bl 3/2009 Self et al. 
7,507,480 B2 3/2009 Sugama 
7,534,453 Bl* 512009 Rzigalinski et al. .......... 424/617 
7,563,459 B2 712009 Phillips et al. 
7,642,250 B2 1/2010 Williams 
7,687,505 B2 3/2010 Sugaya 
7,725,802 B2 5/2010 Eroz et al. 
7,772,375 B2 8/2010 Greferath et al. 
7,888,119 B2 212011 Sugaya et al. 
7,899,093 Bl 3/2011 Bass et al. 
7,906,147 B2 3/2011 Hainfeld et al. 
7,914,617 B2 3/2011 Yadav 
(Continued) 
FOREIGN PATENT DOCUMENTS 
WO WO 99/15891 6/1995 
WO WO 03/059263 A2 7/2003 
(Continued) 
OTHER PUBLICATIONS 
Robert T. Magari. 2003. Assessing shelf life using real-time and 
accelerated stability tests. Biopharm International, vol. 16, Issue 11, 
pp. 36-43.* 
Srivaisan Sathyamurthy, et al., "Reverse Micellar Synthesis of 
Cerium Oxide Nanoparticles" Nanotechnology, 16, (2005) pp. 1960-
1964. 
S. Patil, et al., "Synthesis ofNanocrystalline Ceria Particles for High 
Temperature Oxidation Resistant Coating" Journal ofNanoparticie 
Research, 4, (2002) pp. 433-438. 
(Continued) 
Primary Examiner - Debbie K Ware 
Assistant Examiner - Kailash C Srivastava 
(74) Attorney, Agent, or Firm - Timothy H. Van Dyke; 
Beusse, Wolter, Sanks & Maire, PLLC 
(57) ABSTRACT 
Methods, systems and compositions are disclosed wherein 
normal, non-transformed, healthy biological cells are pro-
tected from oxidative stress, radiation therapy and chemo-
therapy while diseased, transformed cells, such as, cancer 
cells, are provided no protection by the biocompatible, poly-
mer coated nanoceria composition of the present invention. 
The polymer-coated nanoceria preparation herein exhibits no 
toxicity to normal cells and exhibits pH-dependent antioxi-
dant properties at neutral or physiological pH values, between 
approximately 6.5 to approximately 11.0 and is inactive as an 
antioxidant at acidic pH values between approximately 2.0 to 
approximately 6.4. Improved therapeutic agents and cytopro-
tecting devices are based on the newly discovered, pH depen-
dent properties of polymer-coated nanoceria that provide 
selective cytoprotection. 
12 Claims, 21 Drawing Sheets 
US 9,119,391 Bl 
Page 2 
(56) References Cited 
U.S. PATENT DOCUMENTS 






















612011 Seal et al. 
12/2011 Sugaya 
112012 Ketelson et al. 
512012 Altman et al. 
12/2012 Perez et al. 
3/2003 Noth et al. 
7/2003 Gaw et al. 
10/2003 Chane-Ching 
412004 Rezania et al. 
6/2005 Bao et al. 
7/2005 Yoshikawa et al. 
7/2005 Miyabayashi et al. 
8/2005 Gehlsen 
112006 Groman et al. 
512006 Sugaya et al. 
612006 Ivkov 
12/2006 Mistry 
112007 Nangia et al. 
412009 Dai et al. 
412009 Brisson et al. 
612010 Thomas et al. 
712010 Rzigalinski et al. 
FOREIGN PATENT DOCUMENTS 
WO WO 2006/118954 
WO WO 2006/118954 A2 
WO WO 20071002662 
WO WO 20071002662 A2 
WO WO 2008/064357 A2 
WO PCT/US2009/041675 












H.S. Potdar, et al. "Preparation of ceria-ziconia (Ce0.75Zr0.2502) 
powders by microwave-hydrothermal (MH) route" Materials Chem-
istry and Physics, 74, (2002) pp. 306-312. 
David Schubert, et al., "Cerium and yttrium oxide nanoparticles are 
neuroprotective" Biochemical and Biophysical Research Communi-
cations, 342, (2006) pp. 86-91. 
Mukesh G. Harisinghani, et al., "Noninvasive Detection of Clinically 
Occult Lymph-Node Metastases in Prostate Cancer" New England 
Journal of Medicine, vol. 348, No. 25, (Jun. 19, 2003) pp. 2491-2500. 
Rzigalinski, et al. Cerium oxide nanoparticies increase the lifespan of 
cultured brain cells and protect against free radical and mechanical 
trauma, FASEB Journal, 2003, pp. A606, vol, 17, No. 4-5, Abstract 
No. 3377.24. 
Niu, et al., Cardioprotective effects of cerium oxide nanoparticles in 
a transgenic murine model of cardiomyopathy, Cardiovas. Res., 
2006, pp. 549-559, vol. 73, No. 3. 
Qureshi, et al. Increased exhaled nitric oxide following autologous 
peripheral hemotopietic stem-cell transplantation: a potential marker 
of idopathic pneumonia syndrome, Chest, 2004, pp. 281-287, vol. 
125, No. 1. 
Ohgushi, et al., Stem cell technology and biocerarnics: from cell to 
gene engineering, J. Biomed. Mat. Res., 1999, pp. 913-927, vol. 48, 
abstract. 
Dal Maschio, et al., Influence ofCe3+/Ce4+ ratio on phase stability 
and residual stress held in ceria-yttria stabilized zirconia plasma-
sprayed coatings, J. Mat. Sci., 1992, pp. 5591-5596, vol. 27, abstract. 
Rarnsfjell, et al., Distinct requirements for optimal growth and in 
vitro expansion of human CD34+ CD38- bone marrow long-term 
culture-initiating cells (LTC-IC), extended LTC-IC, and murine in 
vivo long-term reconstituting stem cells, Blood, 1999, pp. 4093-
4102, vol. 99, No. 12, abstract. 
Devasenpathi, et al., Forming near net shape free-standing compo-
nents by plasma spraying, Mat. Let., 2002, pp. 882-886, vol. 57. 
Imamura, et al., Drusen, choroidal neovascularization, and retinal 
pigment epithelium dysfunction in SOD 1-deficient mice: a model of 
age-related macular degeneration, PNAS, 2006, pp. 11282-11287, 
vol. 103, No. 30. 
Hollyfield, et al., Oxidative damage-induced inflammation initiates 
age-related macular degeneration, Nature Medicine, 2008. pp. 194-
198, vol. 14. 
Birch, et al., Age-related macular degeneration: a target for 
nanotechnology derived medicines, International Journal of 
Nanomedicine. 2007, pp. 65-77, vol. 2, No. 1. 
Maulik, N., Reactive oxygen species drives myocardial 
angiogenesis?, Antioxidants & Redox Signaling, 2006, pp. 2161-
2168, vol. 8, Nos. 11-12. 
McGinnis, et al. U.S. Appl. No. 12/772,523 Office Action mailed 
Sep. 15, 2011. 
Ohia, et al., Pharmacological consequences of oxidative stress in 
ocular tissues, Mutation Research. 2005, pp. 22-36, vol. 579. 
Liu, et al. Subtype lesions of neovascuiar age-related macular degen-
eration in Chinese patients, Braefe' s Arch Clin Exp Opthalmol, 2007, 
pp. 1441-1445, vol. 245. 
Silva, Seeing the benefits ceria, Nature Nanotechnology, 2006 pp. 
92-94, vol. 1. 
Halm, et al., Maculas affected by age-related macular degeneration 
contain increased chelatable iron in the retinal pigment epithelium 
and Bruch's membrane, Arch. Opthalmol., 2003, pp. 1099-1105, vol. 
121. 
Haywood, et al., Inflammation and angiogenesis in osteoarthritis, 
Arthritis & Rheumatism, 2003, pp. 2173-2177, vol. 48, No. 8. 
Chen, et al., Rare earth nanoparticles prevent retinal degeneration 
induced by intracellular peroxides, Nature Nano Technology, 2006, 
pp. 142-148, vol. 1, No. 2, abstract. 
Moongkarndi, et al., Antiproliferation, antioxidation and induction of 
apoptosis by Carcina mangostana (mangosteen) on SKBR3 human 
breast cancer cell line, J. ofEtlmo-Pharmacology, 2004, pp. 161-166, 
vol. 90, abstract. 
Margrain, et al., Do blue light filters confer protection against age-
related macular degeneration?, Progress in Retinal and Eye 
Research, 2004, pp. 523-531, vol. 23, abstract. 
Bailey, et al., Cerium oxide nanoparticles extend cell longevity and 
act as free radical scavengers, online, retrieved on Apr. 24, 2006, 
retrieved from http://www.med.miarni.edu/rnnbws/Rzigalinskil 1. 
html, abstract. 
Tsai, The study of the synthesis of nano-grade cerium oxide powder, 
Materials Letters, 2004, pp. 2270-2274, vol. 58, abstract. 
Rzigalinski, et al., Ceriurn oxide nanopartides increase the lifespan of 
cultured brain cells and protect against free radical mechanical 
trauma, FASEB Journal, 2003, vol. 17, No. 4-5, p. abstract No. 
377.24, abstract. 
Cook, et al., Neuronal damage induced bypolychlorinated biphenyls 
is partially reversed by cerium oxide nanoparticles, online, 2003, 
retrieved from http:// sfn. schoiarone.corn/itin2003/main.html? new_ 
page_id~ 126&abstract_id~ l 4513&p_num~669.13&is_tech~O>, 
retrieved on Aug. 5, 2008, abstract. 
Tusnekawa, S., et al., Lattice relaxation of monosize Ce02-x 
nanocrystalline particles, Applied Surface Science Elsevier Nether-
lands, 1999, pp. 53-56, vol. 152, No. 1-2, abstract. 
Hooper, et al., New treatment in age-related macular degeneration, 
Clinical Experimental Opthalmology, 2003, pp. 376-391, vol. 31, 
abstract. 
Suzuki, et al., Preparation and characteristics of magnetite-labelled 
antibody with the use of poly( ethylene glycol) derivatives Biotech. 
and Applied Biochem., 1995, pp. 335-345, vol. 21. 
Dung, et al., Activation of glassy carbon electrodes by dispersed 
metal oxide particles, Dept. of Chemistry, OSU, downloaded 2011, 
pp. 813, abstract. 
Shui, et al., Morphological observation on cell death and 
phagocytosis induced by ultraviolet irradiation in a cultured human 
lens epithelial cell line, Exp. Eye Res., 2000, pp. 608-619, vol. 71, 
No. 6, abstract. 
Xijuan, et al., Size-dependent optical properties of nanocrystalline 
Ce02:Er obtained by combustion synthesis, Phys. Chem., 2001, pp. 
5266-5269, vol. 3, abstract. 
Guo, Green and red upconversion luminescence in Ce02:Er3+ pow-
ders produced by 785 nm laser, Journal of Solid State Chemistry, 
2007, pp. 127-131, vol. 180, 1, abstract. 
US 9,119,391 Bl 
Page 3 
(56) References Cited 
OTHER PUBLICATIONS 
Perez, et al., Synthesis of biocompatible dextran-coated nanoceria 
with pH-Dependent antioxidant properties, Small, 2008, pp. 552-
556, vol. 4, No. 5, abstract. 
Pirmohamed, et al., Nanoceria exhibit redox state-dependent catalase 
mimetic activity, Chem. Comm, 2010, pp. 2736-2738, vol. 46, 
abstract. 
Chen, et al., Rare earth nanoparticles prevent retinal degeneration 
induced by intracellular peroxides, Nature Publishing Group, 2006, 
pp. 1-9, abstract. 
Karakoti, et al., Direct synthesis of nanoceria in aqueous 
polyhydroxyl solutions, J. Phys. Chem. C, 2007, pp. 17232-17240, 
vol. 111, No. 46, abstract. 
Tarnuzzer, et al., Vacancy engineered ceria nanostructures for pro-
tection fromradiation-inducedcellular damage, Nano Lett, 2005, pp. 
2573-2577, vol. 4, No. 12, abstract. 
Heckert, et al., The role of cerium redox state in the SOD mimetic 
activity of nanoceria, Biomaterials, 2008, pp. 2705-2709, vol. 29, 
abstract. 
Schubert, et al., Cerium and yttrium oxide nanoparticles are 
neuroprotective, Biochemical and Biophysical Research Communi-
cations, 2006, pp. 86-91, vol. 342. 
Zhang, et al., Cerium oxide nanoparticles: size selective formation 
and structure analysis, Applied Physics Letters, 2002, pp. 127-129, 
vol. 81, No. 1. 
Patil, et al., Surface-derived nanoceria with human carbonic 
anhydrase II inhibitors and flourphores: a potential drug delivery 
device, J. Phys. Chem. C., 2007, pp. 8437-8442, vol. 111, No. 24, 
abstract. 
Patil, et al., Synthesis of nanocrystalline ceria particles for high 
temperature oxidation resistant coating, Journal of Nanoparticle 
Research, 2002, pp. 433-438, vol. 4, abstract. 
Jin, et al., Nanopartical-mediated drug delivery and gene therapy, 
Biotechnol. Prog, 2007, pp. 32-41, vol. 23, abstract. 
Eck, et al., PEGylated gold nanoparticles conjugated to monoclonal 
F 19 antibodies as targeted labeling agents for human pancreatic 
carcinoma tissue, ACS Nano, 2008, pp. 2263-2272, vol. 2, No. 11, 
abstract. 
Nafee, Dissertation entitled "Cationically-modified nanoparticles for 
the polmonary delivery of the telomerase inhibitor 2' -0-Methyl RNA 
for the treatment of lung cancer," Dissertation zur Erlangung des 
Grades des Doktors der, Naturwissenschaftem der Naturwis-
senschaftilch-Technischen Fakul't III Chemie, Pharmazie, Bio-und 
WerstoffWisserischaften der Universit des Saarlandes, 2008, abstract. 
N azem, et al,, Nanotechnology for Alzheimer's disease detection and 
treatment, Insciences J., 2011, pp. 169-193, vol. 1, No. 4, abstract. 
Oliver, et al., Synthesis of pegylated immunonanoparticles, Pharma-
ceutical Research, 2002, pp. 1137-1143, vol. 19, No. 8, abstract. 
Otsuka, et al., PEGylated nanoparticles for biological and pharma-
ceutical applications, Advanced Drug Delivery Reviews, 2003, pp. 
403-419, vol. 55, abstract. 
Qi, et al., Redispersible hybrid nanopowders; cerium oxide 
nanoparticle complexes with Phosphonated-PEG pligomers, ACS 
Nano, 2008, pp. 879-888, vol. 2, No. 5, abstract. 
Sokolov, et al., Real-time vita optical imaging of precancer using 
anti-epidermal growth factor receptor antibodies conjugated to gold 
nanoparticles, Cancer Res. 2003. vol. 63, abstract. 
Suh, et al., Multifunctional nano systems at the interface of physical 
and life sciences, Physicaplus, 2010, issue 13, abstract. 
* cited by examiner 



























oj_~_.. ... j!!!::_-.--.-__,.~.---y--.--,---..~~ 
250 300 350 400 450 500 550 
Wavelength (nm) 
Figure 2 






































































































































































































































































































































































































































































































































910 900 890 880 
Binding energy (eV) 
Figure 5 
US 9,119,391 Bl 
80 
U.S. Patent Sep.1,2015 
Fig. 6A 
Photographic image of 
a first solution of dextran 
coated nanoceria. 
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Fig. 6B 
Photographic image of 
a second solution of 
dextran coated nanoceria. 
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POLYMER COATED CERIA 
NANOPARTICLES FOR SELECTIVE 
CYTOPROTECTION 
RELATED APPLICATIONS 
The present application claims the benefit of priority from 
U.S. Provisional Patent Application Ser. No. 60/949,953 filed 
on Jul. 26, 2007 and is a continuation-in-part of U.S. patent 
application Ser. No. 11/965,343 filed on Dec. 27, 2007, both 
applications are incorporated herein by reference. 
This invention was made with Government support under 
Agency contract number KOi CAI 01781 awarded by the 
National Institutes of Health. The government has certain 
rights in this invention. 
FIELD OF THE INVENTION 
This invention relates to biological uses of nanoceria par-
ticles, and in particular to methods, systems and compositions 
useful in the synthesis of polymer coated ceria oxide nano-
particles for biomedical applications. 
BACKGROUND AND PRIOR ART 
2 
positions for molecular imaging and monitoring wherein the 
magnetic nanoparticle has a biocompatible coating, such as, 
dextran, thereon. 
U.S. Patent Publication 2006/0014938 to Groman et al. 
describes stable aqueous colloidal lanthanide oxides, includ-
ing cerium oxide, some of which are associated with a poly-
mer, including dextran. The colloidal compositions are useful 
as imaging agents in technology requiring injectable chemi-
cals for contrast agents. There is no mention of cerium oxide 
10 coated with polymers having autocatalytic and antioxidant 
properties. 
U.S. Patent Publication 2006/0142749 to Robert Ivkov 
discloses thermotherapeutic compositons for treating dis-
ease. The thermotherapeutic compositions include magnetic 
15 nanoparticles that may be coated to enhance the heating prop-
erties of a bioprobe, particularly if the coating is a polymeric 
material that can include dextran. 
Thus, polymeric coatings including dextran have been 
reported for use on magnetic nanoparticles and the results 
20 seem promising in molecular imaging, monitoring and thera-
peutic treatment of disease. 
In addition, prior to the present invention, most synthetic 
procedures for nanoceria resulted in nanoparticles with poor 
water solubility and provided ceria particles that precipitate 
25 from aqueous solutions. Also, prior art synthetic procedures 
involve the use of toxic solvents, therefore hindering their 
potential clinical use. 
Cerium is a silvery metallic element, belonging to the 
lanthanide group. Cerium oxide (Ce20 3 /Ce02 ) is used in 
precision polishing and lapping applications. Ultra fine nano-
size cerium oxide, less than I 0 nanometers, is more efficient 
for coating purposes. Recently, it was reported by B. Rziga- 30 
linski et al. that nanoparticles prolong the life of cortical 
neurons in culture 4 fold over the cells without treatment, 
decrease the intracellular Ca2+ concentration and prevent UV 
damage of cortical neurons. See B. Rzigalinski et al., 
"Cerium Oxide Nanoparticles Extend Cell Longevity andAct 35 
as Free Radical Scavengers" at website http://www.med.mi-
ami.edu/nmbws/Rzigalinskil 12.html. Based on its chemical 
characteristics, this effect is partially due to a decrease of 
reactive oxygen species (ROS). 
It is desirable to find reliable solutions to use of nanoceria 
particles with antioxidant properties in the treatment of many 
human diseases that are due to the death of cells in specific 
tissues or organs. The majority of those diseases are due to 
accumulation of metabolic insults from reactive oxygen spe-
cies originating within or outside of the cells. These diseases 
include all forms of blindness whether hereditary, light-in-
duced, or physical damage such as occurs in retinal detach-
ment. In addition, damage due to ageing, stroke, cardiac 
infarction, bums, etc, which proceed through reactive oxygen 
species, can be addressed with the nanoceria particles syn-
thesized according the present invention. 
Various investigators have shown that nanoceria particles 40 
possess antioxidant properties and have demonstrated the 
survival of neuron cells in cultures against oxidative stress 
and radiation. 
The ability of nanoceria particles to reversibly switch from 
ce+3 to ce+4 is a key factor in their use in catalytic and 
biological applications as antioxidants. In co-pending U.S. 
application Ser. No. 11/965,343 filed on Dec. 27, 2007, it was 
reported that the polymeric coating does not affect the auto-However, the synthetic procedures for nanoceria reported 
so far are not likely to be approved by the U.S. Food and Drug 
Administration (FDA) because the synthesis procedures 
involve the use of surfactants and other toxic materials. 
In addition, the published synthetic methods result in 
uncoated nanoparticles that are not stable and tend agglom-
erate in aqueous solutions. 
45 catalytic properties of nanoceria, as hydrogen peroxide and 
peroxyl radicals can diffuse through the hydrophilic polymer 
coating and oxidize Ce+3 to Ce+4 . Thus, polymer-coated 
nanoceria particles are used as antioxidants in biomedical 
applications, such as, protection against radiation damage, 
50 oxidative stress and inflammation. 
Further developments in biomedical research reveal the 
efficacy of coated magnetic nanoscale particle compositions 
for therapeutic uses. In Patent Publication W0/2003/005029 
The present application shows that polymer-coated nano-
ceria particles with enhanced biocompatibility and stability in 
aqueous solution exhibit a pH-dependent antioxidant activity 
and provide a means for tailoring reversible and non-revers-to Zhenghe Xu et al. iron and iron oxide particles are coated 
with dextran for biological cell separation using magnetic 
carrier technology. The dextran coating is used to prevent 
mechanical instability of the particle in suspension. 
55 ible antioxidant properties of polymer-coated nanoceria par-
ticles. 
SUMMARY OF THE INVENTION 
The objectives of U.S. application Ser. No. 11/965,343 
filed on Dec. 27, 2007, are also objectives of the present 
invention and are listed below. 
U.S. Patent Publication 2003/0124,194 to Gaw et al. dis-
closes amine functionalized superparamagnetic nanopar-
ticles using a process that consists of coating the magnetic 60 
nanoparticles with a carboxylated polymer then subsequently 
reacting the carboxylated functionalized magnetic nanopar-
ticles with carbodiimide and a large excess of diamine, after 
which the amine-terminated nanopartices are reacted with 
bifunctional crosslinking agents and various biomolecules. 
A primary objective of the present invention is to provide a 
facile, synthetic method for the formation of cerium oxide 
65 (ceria) nanoparticles coated with a biodegradable polymer. 
U.S. Patent Publication 2005/0130167 to Gang Boa, et al. 
provides multifunctional magnetic nanoparticle probe com-
A secondary objective of the present invention is to provide 
a synthetic method for the formation of cerium oxide ( ceria) 
US 9,119,391 Bl 
3 
nanoparticles coated with dextran, a biodegradable polymer 
that can be scaled up for commercial production. 
A third objective of the present invention is to provide 
cerium oxide (ceria) nanoparticles coated with a biodegrad-
able polymer that has physical properties that are substan-
tially identical of the properties of uncoated nanoceria par-
ticles for therapeutic applications. 
A fourth objective of the present invention is to provide 
cerium oxide (ceria) nanoparticles coated with a biodegrad-
able polymer with good solubility and stability in water and 
phosphate buffered saline, with no precipitation for approxi-
mately 12 months. 
A fifth objective of the present invention is to provide a 
facile, synthetic method for the formation of cerium oxide 
(ceria) nanoparticles coated with dextran that is further 
crosslinked with epichlorohydrin and treated with armnonia, 
resulting in an aminated dextran coated ceria nanoparticles to 
create a targetable ceria nanoparticle. 
A sixth objective of the present invention is to provide a 
water stable, biodegradable polymer coated nanoceria prepa-
ration that is biologically active for administration to human 
and other mammals. 
4 
dant, free-radical scavenging and autocatalytic properties of 
the cerium oxide nanoparticles are unchanged from uncoated 
cerium oxide nanoparticles. 
The preferred in situ synthesis method has a biodegradable 
polymer that is at least one of a carbohydrate polymer, a 
synthetic polyol, a carboxylated polymer, and derivatives 
thereof, more preferably, the carboxylated polymer is poly-
acrylic acid. 
It is also preferred that the carboxylated polymer is reacted 
10 with a diamine selected from at least one of ethylene diamine, 
propylene diamine and hexane diamine, to provide an ami-
nated cerium oxide nanoparticle in a reaction that eliminates 
the need for polymer crosslinking. 
The preferred carbohydrate polymer for the in situ synthe-
15 sis method of the present invention is a polysaccharide, such 
as dextran, arabinogalactan, chitosan and the like; most pref-
erably the polysaccharide is dextran. 
In the preferred in situ synthesis method the cerium nitrate 
solution contains approximately 2.0 to approximately 3.0 
20 grams of cerium nitrate to approximately 5 ml of water and 
the plurality of dextran-coated cerium oxide nanoparticles 
has a UV profile exhibiting strong absorption below approxi-
mately 400 nm with peak absorption at approximately 300 
nm. 
A seventh objective of the present invention is to provide a 
water stable, biodegradable polymer coated nanoceria prepa-
ration that has a long circulation time, such as, a plasma 25 
half-life longer than one minute. 
A preferred composition that is useful as a potent antioxi-
dant in biomedical applications includes a plurality of nano-
ceria particles coated with a biodegradable polymer selected 
from at least one of a carbohydrate polymer, a synthetic 
polyol, a carboxylated polymer, and derivatives thereof. The 
more preferred carboxylated polymer is polyacrylic acid. The 
preferred carbohydrate polymer is a polysaccharide, such as, 
dextran, arabinogalactan and chitosan; most preferably, the 
polysaccharide is dextran. 
In the preferred composition, the plurality of dextran-
An eighth objective of the present invention is to provide a 
facile, synthetic method for the formation of cerium oxide 
(ceria) nanoparticles coated with polyacrylic or any other 
polycarboxylic acid polymer that will result in a carboxyl 30 
group functionalized nanoparticle. The ceria nanoparticles 
coated with functionalized carboxyl groups are reacted with a 
diamine, such as ethylenediamine, to create an amine func-
tionalized cerium oxide nanoparticle without the need for 
polymeric crosslinking. 35 coated cerium oxide nanoparticles has a UV profile exhibit-
ing strong absorption below approximately 400 nm with peak 
absorption at approximately 300 nm and the physical prop-
erties of the dextran-coated cerium nanoparticles replicate the 
physical properties of the uncoated nanoceria particles for 
Additional objectives of the continuation-in-part applica-
tion are as follows: 
A ninth objective of the present invention is to provide 
polymer-coated ceria nanoparticles formed in situ for use in 
improved therapeutic agents and cytoprotecting devices. 
A tenth objective of the present invention is to provide a 
biocompatible nanoceria preparation that protects normal 
cells against oxidative stress, while providing no cytoprotec-
tion to cancer or malignant cells. 
A eleventh objective of the present invention is to provide 
smart, pH-dependent therapeutic agents and devices using 
polymer-coated ceria nanoparticles that selectively protect 
healthy tissue and cells from free radicals, but do not protect 
transformed cell lines due to the acidic microenvironment of 
the transformed cells. 
A twelfth objective of the present invention is to provide 
pH-dependent therapeutic agents and devices using polymer-
coated ceria nanoparticles that exhibit reversible and non-
reversible antioxidant behavior. 
40 therapeutic applications as antioxidants, free-radical scaven-
gers and autocatalytic agents. 
In the preferred composition, the plurality of dextran-
coated cerium oxide nanoparticles form a colloidal suspen-
sion that is stable in water and form a colloidal suspension 
45 that is stable in a phosphate buffer saline solution. 
A more preferred composition of matter that is useful as an 
antioxidant, free-radical scavenger and autocatalyst in bio-
medical applications includes a plurality of nanoceria par-
ticles coated with a crosslinked-aminated biodegradable 
50 polymer selected from at least one of a carbohydrate polymer, 
a synthetic polyol, a carboxylated polymer, and derivatives 
thereof. The preferred carbohydrate polymer is a polysaccha-
ride such as, dextran, arabinogalactan and chitosan; the most 
preferred polysaccharide is dextran. 
The preferred composition has a plurality of dextran-
coated cerium oxide nanoparticles with a UV profile exhib-
iting strong absorption below approximately 400 nm with 
peak absorption at approximately 300 nm and the physical 
properties of the dextran-coated cerium nanoparticles repli-
A preferred in situ method forthe synthesis of a plurality of 55 
cerium oxide nanoparticles coated with a biodegradable poly-
mer for antioxidant, free-radical scavenging and autocatalytic 
biomedical applications, includes preparing an aqueous 
cerium nitrate solution, mixing the aqueous cerium nitrate 
solution with a biodegradable polymer to form a first mixture, 
adding the first mixture dropwise to an armnonium hydroxide 
solution while continuously stirring to form a second mixture, 
centrifuging the second mixture containing ammonium 
hydroxide to settle any debris or large particles, purifying the 
centrifuged mixture by ultrafiltration, and recovering a plu-
rality of non-agglomerated cerium oxide nanoparticles 
coated with the biodegradable polymer wherein the antioxi-
60 cate the physical properties of the uncoated nanoceria par-
ticles for therapeutic applications as antioxidants, free-radi-
cal scavengers and autocatalytic agents. 
The more preferred composition has a plurality of dextran-
coated cerium oxide nanoparticles that form a colloidal sus-
65 pension that is stable in water and also form a colloidal 
suspension that is stable in a phosphate buffered saline solu-
ti on. 
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Further objects and advantages of the present invention 
will be apparent from the following detailed description of a 
presently preferred embodiment which is illustrated sche-
matically in the accompanying drawings. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 shows the UV-visible absorption spectrum of the 
dextran coated nanoceria prepared in the present invention. 
FIG. 2 is the fluorescence spectra of dextran coated cerium 10 
oxide nanoparticles O'-ex =283 nm) showing a characteristic 
fluorescence peak at approximately 410 nanometer (nm) 
wavelength. 
FIG. 3 shows the measurement of zeta-potential in the 
analysis of the stability of nanoparticle preparation against 15 
agglomeration within biological systems. 
FIG. 4 shows the X-ray diffraction pattern ofnanocrystal-
line cerium oxide coated with dextran in the present inven-
tion. 
FIG. 5 shows the X-ray photon spectroscopy spectrum of 20 
the synthesized cerium oxide nanoparticles coated with dex-
tran showing the presence of a mixed valence (Ce3+ and 
Ce4+) state. 
6 
FIG. llB is a graph showing the percent viability ofnormal 
dermal fibroblasts cell cultures untreated and treated with 
dextran coated nanoparticles, hydrogen peroxide and a com-
bination of dextran coated nanoparticles and hydrogenperox-
ide. 
FIG. 12 is an X-ray photon spectroscopy (XPS) spectra of 
the aminated nanoceria showing the presence of a mixed 
valence, ce+3 and ce+4 similar to the spectrum of dextran 
coated nanoceria that is not aminated. 
FIG. 13 is an X-ray photon spectroscopy (XPS) spectrum 
of the polyacrylic acid coated nanoceria (PAA-nanoceria) 
showing the presence of a mixed valence, ce+3 and ce+4 
similar to the spectrum of dextran coated nanoceria and ami-
nated dextran coated nanoceria shown in FIG. 12. 
FIG. 14 is a diagram depicting the in-situ formation of 
stable cerium oxide nanoparticles coated with dextran poly-
mer as stabilizer. 
FIG. 15 is a Fourier Transform Infrared (FT-IR) spectra of 
pure dextran and dextran-coated cerium oxide nanoparticles. 
FIG. 16 is an FT-IR spectra of a representative dextran 
coated nanoceria preparation compared to that of pure dext-
ran, indicating the presence of characteristic dextran IR bands 
in dextran coated nanoceria. 
FIG. 6A is a photographic image of a first solution of 
dextran coated nanoceria after ultrafiltration with an Amicon 
30 K filter. 
FIG. 17 A shows reversible color changes in a solution of 
25 dextran-coated nanoceria at pH 7.4, on addition of hydrogen 
peroxide. 
FIG. 6B is a photographic image of a second solution of 
dextran coated nanoceria after the solution is concentrated 
using a 30K Centricon concentrator. 
FIG. 7A is a transmission electron microscopy (TEM) 30 
image of the dextran coated ceria nanoparticles showing the 
size and dispersity of the ceria crystals. 
FIG. 17B shows irreversible color changes in a solution of 
dextran-coated nanoceria at pH 4.0, on addition of hydrogen 
peroxide. 
FIG. 18 is a graph of the transmittance spectra showing 
reversible autocatalytic behavior for dextran coated nanoc-
eria when incubated with hydrogen peroxide at pH 7.4. 
FIG. 7B is a high resolution transmission electron micros-
copy (HRTEM) image of the dextran coated ceria nanopar-
ticles showing that the coating does not affect the crystallin-
ity. 
FIG. 19 is a graph of the transmittance spectra showing 
irreversible autocatalytic behavior for dextran coated nanoc-
35 eria when incubated with hydrogen peroxide at pH 4.0. 
FIG. 7C is a selected area electron diffraction (SAED) 
image of a single ceria crystal showing that the dextran coated 
ceria crystal is a face-centered cubic (FCC) phase crystal. 
FIG. 8 is a graph showing the increase in particle size with 40 
time upon concanavalin addition. 
FIG. 9 is a graph showing reversible and successive shift in 
transmittance of dextran coated nanoceria particles after add-
ing hydrogen peroxide (Days 1-10). 
FIG. lOA is a real-time image of dextran nanoceria solu- 45 
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day one. 
FIG. lOB is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day three. 
FIG. lOC is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day seven. 
50 
FIG. lOD is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro- 55 
gen peroxide on the right at day ten. 
FIG. 20 shows the effect of dextran-coated nanoceria on 
lung carcinoma. 
FIG. 21 shows the effect of dextran-coated nanoceria on 
breast carcinoma cells. 
FIG. 22 is a graph showing the percent viability of normal 
cardiomyocyte cell cultures protected from nitroxyl radical 
induced toxicity when treated with dextran coated nanopar-
ticles versus no treatment with dextran coated nanoceria. 
FIG. 23 is a graph showing the percent viability of normal 
cardiomyocyte cell cultures protected from nitroxyl radical 
induced toxicity when treated with aminated dextran coated 
nanoparticles versus no treatment with aminated dextran 
coated nanoceria. 
DESCRIPTION OF THE PREFERRED 
EMBODIMENTS 
Before explaining the disclosed embodiments of the 
present invention in detail it is to be understood that the 
invention is not limited in its application to the details of the 
particular arrangements shown since the invention is capable 
of other embodiments. Also, the terminology used herein is 
for the purpose of description and not of limitation. 
FIG. lOE is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day ten after adding fresh hydro-
gen peroxide. 
FIG. lOF is a real-time image of dextran nanoceria solu-
tions without hydrogen peroxide on the left and with hydro-
gen peroxide on the right at day twenty. 
The term "nanoceria" is used interchangeably with 
60 "cerium oxide nanoparticles" and is used to refer to the 
cerium oxide particles of multiple valences. 
FIG. llA is a graph showing the percent viability ofnormal 
cardiomyocyte cell cultures untreated and treated with dext- 65 
ran coated nanoparticles, hydrogen peroxide and a combina-
tion of dextran coated nanoparticles and hydrogen peroxide. 
The term "biodegradable polymer" is used herein to 
describe a class of polymers that are non-toxic to mammals 
and the environment and more specifically, include dextran, 
derivatives of dextran such as reduced dextran, carboxyl 
methyl reduced dextran, a polyol polymer or carbohydtrate 
polymer, synthetic polyols, carboxylated polymers, such as 
US 9,119,391 Bl 
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polyacrylic acid, and other polysaccharides, such as, but not 
limited to, arabinogalactan, and chitosan as disclosed in Gro-
man et al. U.S. Patent Publication 2006/0014938 and Gaw et 
al. U.S. Patent Publication 2003/0124,194. 
In the present invention, the cerium oxide nanoparticles or 
nanoceria are polymer associated, or, in other words, coated 
with a biodegradable polymer. The polymer confers stability 
in water and can be functionalized with carboxylic or amino 
groups for conjugation with proteins, peptides, oligonucle-
otides, small molecules, and the like. 
10 
Further, as will be explained in detail, the antioxidant activ-
ity of the polymer coated nanoceria particles is significantly 
reduced in a acidic pH, from approximately 2 to approxi-
mately 6; however, in the pH range from approximately 7 to 
approximately 11, the polymer-coated nanoceria particles are 
very active antioxidants, thus permitting the design of 15 
improved therapeutic devices, such as, in the radioprotection 
of healthy tissue during radiation therapy of acidic tumors. 
In general, the polymer coated nanoceria particles of the 
present invention each have a size between approximately 1 
nanometer (nm) to approximately 500 nm in diameter, pref- 20 
erably between approximately 1 nm and approximately 10 
nm. For example, the nanoceria particles used herein are 
composed of a cerium oxide core that is approximately 4 
nanometers (nm) in diameter surrounded by a dextran coating 
for a total nanoparticle size of approximately 10 nm in diam- 25 
eter, as illustrated in FIG. 14. 
Briefly, an aqueous solution of cerium nitrate and dextran 
is added to an ammonia solution under continuous stirring. 
Upon formation of the cerium oxide nanocrystals, molecules 
of dextran coat the nanoparticle surface, preventing further 
30 growth and resulting in dextran coated nanoceria. FIG. 8 
shows time dependent size increase that is observed on con-
canavalin A induced clustering of dextran nanoceria in phos-
phate buffered saline (PBS). 
Further stabilization and functionalization of the nanopar-
ticle is achieved by crosslinking the dextran coating with 35 
epichlorohydrin, followed by treatment with anmionia to 
yield aminated dextran-coatednanoceria (ANC) as illustrated 
in FIG.15. 
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( 5 g in 10 ml of water) to form mixture (I). Under continuous 
stirring, the mixture (I) is then added dropwise to 30 ml of 
29% anmionium hydroxide solution (Fischer, USA) forming 
mixture (II). Mixture (II) is then stirred continuously for 24 
hours. After 24 hours of stirring, the solution turns from a 
light yellow to a deep brown color. The preparation is centri-
fuged at a rate of 4000 rpm for two 30-minute cycles to settle 
down any debris and large particles. The preparation is then 
purified from free dextran by ultrafiltration using a 30 K 
Amicon filter. 
Example 2 
Crosslinking and Amination of Dextran Coated Ceria 
with Epichlorohydrin 
Dextran coated ceria nanoparticles are crosslinked with 
epichlorohydrin using the following procedure under ambi-
ent conditions: 
To 3 ml (3 volume) of dextran coated nanoceria particle 
preparation in Example 1, 5 mL (5 volumes) of5MNaOHare 
added while stirring. Then, 2 mL (2 volumes) of epichloro-
hydrin are added to the stirring solution. The ceria nanopar-
ticle suspension is stirred vigorously for 8 hours at room 
temperature. Then, 8.5 mL (8.5 volumes) of30% ammonia is 
added and stirred overnight at room temperature. The next 
day, the excess epichlorohydrin and ammonia are removed by 
ultrafiltration and the nanoparticle buffer is exchanged to 
0.025 M Na-Citrate buffer pH 8. At this point, the aminated 
dextran nanoceria preparation can be concentrated without 
precipitation of the nanoparticles. 
Epichlorohydrin is used as the crosslinking agent in 
Example 2, however, it is understood by those skilled in the 
art that other crosslinking agents may be used, such as glut-
araldehyde, bromide derivatives of cyanogens and the like. 
The dextran-coated nanoceria (DNC) and aminated dext-
ran-coated nanoceria (ANC) preparations are both stable in 
water and phosphate buffered saline (PBS) at concentrations Methods of preparing the biodegradable polymer coated 
cerium oxide compositions for use as an antioxidant and 
protection from damaging ultra violet (UV) radiation are 
provided in detail below. 
The first embodiment of the present invention provides an 
in situ method and procedure for synthesizing a biodegrad-
able polymer coated ceria nanoparticle for antioxidant and 
autocatalytic biomedical applications. 
40 of 40 mM or higher with no precipitation for months. DNC 
andANC demonstrate good water stability even after several 
heating cycles (70 to 80° C.) and no sedimentation ofnano-
particles in PBS or citrate buffer is observed upon centrifu-
gation at 8,000 rpm for 30 minutes. These characteristics 
The second embodiment of the present invention provides 
a method and procedure for synthesizing aminated cross-
linked dextran coated ceria nanoparticles for antioxidant and 
autocatalytic biomedical applications. 
The third embodiment of the present invention provides a 
method and procedure for synthesizing non-crosslinked, car-
boxylated polymer coated ceria nanoparticles to provide an 
amine functionalized nanoparticle for antioxidant and auto-
catalytic biomedical applications. 
45 make the water-based in situ method advantageous over 
organic solvent based preparations, which are prone to aggre-
gation when suspended in aqueous media. The ANC prepa-
ration has, on average, 3 .4 mM of amine per gram of cerium 
that could be used to conjugate targeting ligand and dyes to 
50 allow optical tracking of the nanoparticles. 
It is a primary concern that the physical properties of the 
biodegradable polymer coated ceria nanoparticles remain 
unaffected by the coating which improves handling and appli-
cation for biomedical purposes. 
In FIG. 1, the UV profile for the dextran coated nanoceria 
is shown. Dextran coated ceria particles show strong absorp-
tion below 400 nm with peak absorption maximum at 300 nm. 
The UV profile of the dextran coated nanoceria prepared in 
the present invention is similar to that obtained in previous 
The examples below provide further detail on the synthesis 55 
and physical characterization of the biodegradable polymer 
coated ceria nanoparticles of the present invention. Dextran is 
used as an exemplary polymeric coating, not a limitation of 
the present invention; other biodegradable polymers may be 
judicially selected by a person of skill in the art. 60 work showing that naked or uncoated ceria nanoparticles 
have well defined peak absorption around 305 nm. Thus, the 
UV profile of the coated and uncoated nanoceria is substan-
tially the same. 
Example 1 
Synthesis ofDextran Coated Ceria Nanoparticles 
Under ambient conditions, a 1 M cerium nitrate solution 
(2.17 gin 5 ml of water) was mixed with a IM Dextran T-10 
In FIG. 2 the fluorescence spectra of dextran coated nano-
65 ceria particles of the present invention has a characteristic 
fluorescence peak around 410 nm and is similar to the fluo-
rescence spectra of the uncoated nanoceria particles reported 
US 9,119,391 Bl 
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by S. Sathyamurthy et al. in "Reverse Micellar Synthesis of 
Cerium Oxide Nanoparticles" Nanotechnology 16 (2005) 
1960-1964. 
To analyze the stability of nanoparticle preparation against 
agglomeration within biological systems, zeta-potential mea-
surement is performed. In pure water, the zeta-potential mea-
surements of oxide dispersions cover a wide range from -25 
to 55 mV. 
10 
ConcanavalinA is a protein with four binding sites, known 
to bind carbohydrates. This protein has been used to induce 
the clustering of dextran-coated gold nanoparticles and most 
recently it was used in the clustering of iron oxide nanopar-
ticles. It is used to study how the clustering phenomenon 
changes the optical (gold nanoparticles), or magnetic (iron 
oxide) properties of the nanoparticles. It is used to verify 
whether the dextran is associated to (coating) the nanopar-
ticle. In these studies, dextran coated nanoceria is incubated Due to the presence of dextran polymer on the surface of 
the nanoparticle, its charge distribution would be affected and 
the zeta potential would be shifted toward more positive and 
less negative values. The dextran coated nanoceria prepara-
tion of the present invention has a zeta potential of -5 .7 m Vas 
shown in FIG. 3. 
10 with concanavalin A and a time-dependent increase in the 
particle size is observed as measured by dynamic light scat-
tering (DLS). This increase in "size" by light scattering is not 
due to an increase in the size of the nanoparticles, but rather is 
due to the clustering of the nanoparticles in solution. FIG. 8 
15 shows that after 90 minutes incubation with concanavalin, 
nanoparticle clusters of 650 nm in size are observed thus, 
showing the increase in particle size with time upon con-
canavalin addition. 
The X-ray diffraction (XRD) pattern for the dextran coated 
nanoceria is shown in FIG. 4. The diffraction peaks found in 
the coated nanoceria are in a good agreement with those 
found in bulk ceria and preparation of uncoated nanoceria, as 
determined by the earlier investigator (W. Chengyun et al, 20 
2002, S. Sathyamurthy et al, 2005). The broadening of the 
peak suggests that the particles are of small dimension. The 
particle size, which can be calculated using the Scherrer 
equation, is around 3 nm, which is in agreement with the data 
obtained by TEM. Also XRD (X-ray diffraction) confirms 25 
that coated nanoceria particles have (111 ), (220), (311) and 
(331) planes which are in good agreement with the lattice 
planes identified by selected-area electron diffraction 
(SAED). 
X-ray photon spectroscopy (XPS) data in FIG. 5 show the 30 
presence of a mixed valence state, indicating that the dextran 
coating on the nanoparticle does not affect the mixed valence 
state, a key physical property of nanoceria. The data also 
show that the amount of Ce+3 ion in the nanoparticle is more 
than the amount of Ce+4 ion, in agreement with the small 35 
particle size ( ofless than 5 nm) as reported by D. Schubert et 
al., Biochemical and Biophysical Research Communications 
2006, 342, 86. In addition, dynamic light scattering (DLS) 
studies revealed a monodisperse size distribution for DNC 
with an average diameter of approximately 10 nanometers 40 
(nm). 
FIG. 6A is a photographic image of a sample of dextran 
nanoceria in aqueous solution wherein the vial on the left 
corresponds to a solution of dextran nanoceria obtained fol-
lowing the procedure we are disclosing in this invention dis- 45 
closure, after ultrafiltration with an Amicon 30 K filter as 
described in Example 1. When a sample of this solution is 
concentrated using a 30K Centricon concentrator, a more 
concentrated dextran coated nanoceria is obtained, as shown 
in FIG. 6B, the vial on the right, with a darker solution. No 50 
precipitation of agglomeration is observed in any of the two 
solutions, showing the great stability ofthis nanoceria prepa-
ration in aqueous solution. 
The addition of glucose to the nanoceria preparation before 
concanavalin incubation abrogated the assembly of the nano-
particles, suggesting that the observed changes in particle size 
distribution were due to the concanavalin-dextran interaction 
on the nanoparticle surface. 
Autocatalytic behavior of dextran-coated nanoceria was 
studied with addition of hydrogen peroxide. One of the most 
interesting properties ofnanoceria is its autocatalytic behav-
ior. The ability of these nanoparticles to reversibly switch 
from ce+3 to ce+4 , is a key factor for their biological appli-
cations as an antioxidant, among others. Therefore, it is deter-
mined whether the dextran coating on the nanoceria prepara-
tion compromised its autocatalytic behavior. In these 
experiments, the nanoparticles are oxidized using hydrogen 
peroxide. It is observed that after adding hydrogen peroxide, 
as an oxidizer, to the nanoceria there is a red shift and also 
color changes to dark orange/brown (Ce+4). As the hydrogen 
peroxide decomposes from the nanoparticle suspension, the 
observed brown color starts to disappear and the solution 
color returns to yellow (Ce+3 ) within ten days as shown in 
FIG. 9. In FIG. 9, note the reversible and successive shift in 
transmittance of dextran coated nanoceria particles after add-
ing hydrogen peroxide on day one a, % transmittance plotted 
against the wavelength, is between approximately 475 nm to 
approximately 700 nm, at day 2 b, % transmittance is between 
approximately 410 nm to approximately 600 nm, day 3 c, % 
transmittance is between 400 nm and approximately 550 nm; 
days 4-10 d-j, after the addition of hydrogen peroxide and the 
decomposition of hydrogen peroxide nears completion, the 
plot of the % transmittance against wave length is within a 
narrower range between approximately 400 nm and approxi-
mately 450 nm wavelength, confirming the disappearance of 
the brown color. 
Autocatalytic activity is represented in Equation (1) below: 
2ce•3(aq)+H202+2H+(aq)~2ce•4(aq)+2H20 (1) 
FIGS. lOA-lOF are real-time images of dextran coated 
nanoceria solutions with and without hydrogen peroxide. 
FIG. lOA shows a dextran-coated nanoceria solution without 
hydrogen peroxide on the left 5 and with hydrogen peroxide 
on the right 10 at day one. FIG. lOB shows a dextran-coated 
nanoceria solution without hydrogen peroxide on the left 15 
and with hydrogen peroxide on the right 20 at day three. FIG. 
lOC shows dextran nanoceria solutions without hydrogen 
peroxide on the left 25 and with hydrogen peroxide on the 
right 30 at day seven. FIG. lOD shows dextran nanoceria 
Further characterization of the dextran coated nanoceria 
preparation is provided in FIGS. 7 A, 7B and 7C showing the 55 
high crystallinity of the nanoceria particles of the present 
invention. FIG. 7A is a transmission electron microscopy 
(TEM) image of the dextran coated ceria nanoparticles show-
ing the size and dispersity of the ceria crystals. FIG. 7B is a 
high resolution transmission electron microscopy (TEM) 60 
image of the dextran coated ceria nanoparticles, showing that 
the coating does not affect the crystallinity. FIG. 7C is a 
selected area electron diffraction (SAED) image of a single 
ceria crystal showing that the dextran coated ceria crystal is a 
FCC phase crystal. 65 solutions without hydrogen peroxide on the left 35 and with 
hydrogen peroxide on the right 40 at day ten. FIG. lOE shows 
dextran nanoceria solutions without hydrogen peroxide on 
Concanavalin A studies were used to verify the dextran 
coating of the ceria nanoparticles of the present invention. 
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the left 45 and with hydrogen peroxide on the right 50 at day 
ten after adding fresh hydrogen peroxide on the tenth day. 
FIG. lOF shows dextran nanoceria solutions without hydro-
gen peroxide on the left 55 and with hydrogen peroxide on the 
right 60 at day twenty. The real-time images confirm the 
autocatalytic activity shown in FIG. 9; there are color changes 
as the hydrogen peroxide decomposes from contact with the 
nanoparticle suspension. 
12 
FIGS. 9, lOA to lOF demonstrate the reversibility of the 
antioxidant activity of polymer-coated nanoceria solutions at 
normal physiological conditions. Subsequent addition of 
hydrogen peroxide in FIG. lOE, after 10 days, brought the 
color of the solution back to orange/brown which again 
started to disappear within the next 10 days (FIG. lOF). This 
15 
reversible and cyclical autocatalytic behavior at physiologi-
Preliminary characterization of this preparation shows that 
indeed the dextran surface contains reactive amino groups 
that can be used to conjugate targeting ligands and various 
dyes, including near infrared dyes that would allow in vivo 
optical tracking of the nanoparticle. Furthermore, this amine 
group, which has a positive charge at physiological pH, can be 
reacted with a succinic anhydrate, resulting in a carboxylated 
or negatively charged nanoceria preparation, greatly expand-
ing the conjugation capabilities of the aminated preparation. 
1° FIG. 12 is an X-ray photon spectroscopy (XPS) spectrum 
of the aminated crosslinked nanoceria showing the presence 
of a mixed valence, Ce+3 and Ce+4 similar to the spectrum of 
dextran coated nanoceria that is not aminated. 
cal conditions is essential for free radical scavenging and 
antioxidant properties of nanoceria and its potential medical 
applications. 
Physical properties of the aminated dextran coated nanoc-
eria were analyzed by X-ray photon spectroscopy to deter-
mine whether the crosslinking procedure would affect the 
presence ofboth ce+3 and c+4 and therefore its biological and 
autocatalytic activity. As shown in FIG. 12, the presence of 
With regard to biological activity, preliminary biological 
data shows that, as expected, the dextran-coated nanoceria 
preparation act as potent antioxidant agents. In these experi-
ments, normal human cell cultures are exposed to hydrogen 
peroxide. This treatment causes a high level of cellular stress, 
similar to that experienced by cells under oxidative damage. 
The data show that in the absence of dextran nanoceria 
(DNC), from approximately 50% to approximately 95% of 
the cells died upon addition of hydrogen peroxide, whereas 
most of them survive this harsh treatment when in the pres-
ence of dextran coated nanoceria (DNC). 
20 both ce+3 and ce+4 species in the aminated dextran coated 
nanoceria are similar to those obtained with non-crosslinked 
nanoceria. This indicates that crosslinking of the dextran does 
not affect the dual valency (Ce+3 /Ce+4 ) in the nanoceria 
preparation of the present invention and most likely will not 
25 affect its autocatalytic/antioxidant properties. Biological uses 
of the crosslinked, biodegradable polymer-coated nanoceria 
include administration to human and other mannnals needing 
antioxidant treatments to prolong cell life. 
30 
FIGS. llA and llB are graphs of percent viability of 
normal cell cultures, cardiomyocytes and dermal fibroblast, 
respectively. In FIGS. llA and llB, the control is untreated 
and thus 100% viable; the cells treated with dextran coated 
nanoceria (DNC) are 100% viable and the cells treated with a 35 
combination of dextran coated nanoparticles (DNC) and 
hydrogen peroxide are 100% viable. However, FIG. llA 
shows that normal cell cultures of cardiomyocytes are 
approximately 5% viable when treated with or exposed to 
only hydrogen peroxide and FIG. llB shows that normal cell 40 
cultures of dermal fibroblasts are approximately 50% viable 
when treated with hydrogen peroxide without dextran coated 
ceria nanoparticles (DNC). Thus, FIGS. llA and llB are 
graphical illustrations of the effectiveness of dextran coated 
ceria nanoparticles as potent antioxidant agents that promote 45 
100% cell viability in the presence of deadly oxidizing 
agents. 
The crosslinking and amination of dextran coated ceria 
with epichlorohydrin as discussed in Example 2 above, was 
studied to determine whether the anti-oxidant properties of 50 
the nanoceria particles could be extended to injectable or 
targetable biomedical applications. 
The dextran coated nanoceria prepared according to 
Example 1 shows great stability in water and various aqueous 
buffers, such as 0.1 M phosphate buffer, pH 7.4, without 55 
compromising its autocatalytic and antioxidant properties. 
However, the surface of this nanoparticle cannot be easily 
modified with targeting ligands such as peptides, oligonucle-
otides and proteins. To advance these studies, the polymeric 
dextran coating has been crosslinked on the surface of the 60 
ceria nanoparticle using epichlorohydrin and further deriva-
tized its surface with annnonia to yield an aminated dextran 
coated nanoceria. As discussed earlier, it is known in the art to 
use other crosslinking agents and the present invention incor-
porates by reference, other known crosslinking agents, such 65 
as, but not limited to, glutaraldehyde, bromide derivatives of 
cyanogens, and the like. 
Example 3 
Carboxylated Polymer Coating ofNanoceria 
Particles 
In another embodiment, following the procedure outlined 
in Example 1, wherein under ambient conditions, a 1 molar 
solution of a polyacrylic acid is used in place of the 1 molar 
solution of dextran, nanoceria particles are coated with a 
biodegradable polymer containing a plurality of carboxylic 
groups ( carboxylated polymer), wherein a portion of the car-
boxyl groups are associated with the cerium oxide surface and 
a portion of carboxyl groups are exposed on the nanoparticle 
surface and available for conjugation. The carboxylated 
nanoparticle can be reacted with a diamine, such as ethylene 
diamine, and correspondingly converted to an amine func-
tionalized nanoparticle. 
Synthesis Method. 
The preparation of polyacrylic acid coated nanoceria 
(PAA-nanoceria) involves the use of cerium (III) nitrate and 
polyacrylic acid (PAA). 1 M cerium (III) nitrate (Aldrich, 
99%) solution(2.17 grams in 5.0milliliters (ml) ofwater)was 
mixed with 0.5 mM solution of PAA (Sigma) to form mixture 
(I). With continuous stirring, the cerium nitrate and PAA 
mixture (I), is added drop wise to 30.0 ml of29% annnonium 
hydroxide (Sigma Aldrich, 30%) solution to form mixture II. 
Subsequently, mixture (II) is stirred continuously for 24 
hours; at this point, the solution has changed from a light 
yellow to a deep brown color. Next, the stirred mixture (II) is 
centrifuged at 4000 rpm for two 30 minute cycles to settle 
down any debris and large particles. The centrifuged solution 
is then purified from free PAA by ultrafiltration using 30K 
molecular weight cut-off Amicon filter (Millipore, Inc.) The 
resulting negative charge on the PAA-nanoceria is assessed 
by zeta potential analysis. 
Below is a schematic diagram (2) of the synthesis ofpoly-
acrylic acid coated nanoceria (PAA-nanoceria). 












Note that the nanoparticles are functionalized with car-
boxylic groups on the surface, which allows conjugation of 
peptides, DNA oligonucleotides, proteins, antibodies and 
small molecules for targeting applications, without the need 
for crosslinking the polymer. 
Furthermore, the carboxylic groups on the polyacrylic acid 
nanoceria can be converted to reactive amine groups by the 
reaction with a water soluble diamine, such as ethylene 
diamine, in the presence of a water soluble carbodiimide as 
disclosed in Gaw et al., U.S. Patent Publication 2002/ 
0124194 for coating of iron oxide nanoparticles as MRI con-
trast agents. 
PAA-nanoceria possesses similar autocatalytic activity as 
regular, non-coated nanoceria, dextran coated nanoceria, and 
aminated dextran coated nanoceria. In addition, PAA-nano-
ceria contains both Ce4 + and Ce3 + (mixed valance) on the 
nanoparticle which is important for its autocatalytic and anti-
oxidant activity as shown in FIG.13. The X-ray photon spec-
troscopy (XPS) image of polyacrylic acid coated nanoceria 
(PAA-nanoceria) in FIG. 13 is substantially similar to the 
X-ray photon spectroscopy (XPS) image of dextran coated 
nanoceria and aminated dextran coated nanoceria shown in 
FIG. 12. This indicates that the PAA-nanoceria will behave 
like the other polymer coated nanoceria preparations dis-
closed herein. 
Prior to the present invention, a facile, cost effective, non-
toxic synthesis of biodegradable polymer coated nanoceria 
particles was not available. The synthesis does not require 
surfactants or vigorous experimental conditions and the end-
product is suitable for unlimited biomedical applications. 
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coating is the ability to form conjugates with various ligands, 
such as peptides, antibodies, DNA-oligonucleotides, proteins 
and small molecules, to create a targetable ceria nanoparticle. 
This would allow targeting or "homing" of the nanoparticle to 
the corresponding site of inflammation or disease. 
All embodiments of the present invention are useful in 
forming colloidal compositions which include nanoparticle 
suspensions of cerium oxide coated with a biodegradable 
polymer. The resulting colloidal composition is highly stable 
10 in water and water-based buffers, such as phosphate saline 
buffer and the like. The colloidal compositions are also suit-
able for concentration and sterilization by filtration. 
Similar procedures have been used in the preparation of 
carboxylated coated iron oxide nanoparticles, allowing for 
15 the creation of targeted molecular imaging agent for MRI as 
reported in Gaw et al. U.S. Patent Publication 2003/0124, 194; 
the teaching with regard to use of carboxylated polymers is 
incorporated herein by reference. 
Some dextran coated iron oxide nanoparticles have been 
20 approved by the FDA for various applications including MRI 
imaging oflymphnodes as reported by M. G. Harisinghani, et 
al. in New England it of Medicine 2003, 348, 2491. 
The newly developed synthesis of biodegradable polymer 
coated ceria nanoparticles presented herein would be ideal for 
25 clinical applications and a candidate for FDA approval. It was 
an unexpected finding that the physical properties of the 
biodegradable polymer coated ceria nanoparticles remain 
unaffected by the polymeric coating which substantially 
improves handling and application for antioxidant and auto-
30 catalytic biomedical applications. 
Thus, polymer-coated and functionalized nanoceria par-
ticles show great stability with no precipitation for more than 
six months stored at room temperature. FT-IR spectra shown 
in FIG. 16 confirms the presence of dextran coating on the 
35 coated ceria nanoparticles confirming that dextran is a vital 
part of the nanoparticles, since characteristic IR peaks of 
dextran are also present in the dextran-coated nanoceria 
(DNC) spectrum. The FT-IR analysis reveals the presence of 
dextran in the synthesized nanoceria and substantiates the 
40 complete surface passivation of the ceria nanocrystal by dex-
tran. 
Prior to the present invention, it was not known that a 45 
biodegradable polymeric coating of ceria nanoparticles 
would not affect the autocatalytic and antioxidant properties 
The great stability with no precipitation and the presence of 
dextran as an integral part of the ceria nanoparticles supports 
a finding of high stability of the DNC under physiological 
conditions and testing of dextran-coated nanoceria solution in 
phosphate-buffered saline (PBS) in a pH range of approxi-
mately 7.4 to approximately 11.0 where reversible antioxi-
dant behavior is observed. of the ceria nanoparticles. 
A biodegradable polymer coated nanoceria exhibits good 
solubility and stability in water and phosphate buffer saline. 50 
The preparation has good stability over many days in the 
buffer solution which is advantageous over the preparations 
which aggregate when redispersed in aqueous media. This 
characteristic makes them suitable for biomedical applica-
tions and clinical use. Further, there is no problem with 55 
agglomeration in aqueous solution over a long period of time, 
as with preparations using a sol-gel technique as reported by 
H. S. Potdar et al. in Materials Chemistry and Physics, 2002 
74, 306. 
Further advantages of the biodegradable polymer coated 60 
cerium oxide nanoparticle include a suspension that can be 
concentrated using ultrafiltration devices without agglomera-
tion of the nanoparticles. 
With regard to the second embodiment, the dextran coating 
on the nanoparticle can be crosslinked with epichlorohydin 65 
and ammonia, resulting in an aminated dextran coated ceria 
nanoparticles. The major benefit of the crosslinked dextran 
New Properties of Polymer-Coated Cerium Oxide Nano-
particles. 
Under acidic pH conditions, polymer-coated cerium oxide 
nanoparticles do not exhibit reversible antioxidant behavior. 
FIGS. 17B, and 19 show that at pH 4.0, the oxidation capa-
bility of dextran-coated nanoceria (DNC) is not reversible, in 
contrast to, FIGS. 17Aand18 where the tests were conducted 
at neutral pH or alkaline conditions which are comparable to 
physiological conditions. 
In FIG. 17A, the addition of hydrogen peroxide at ten-day 
intervals caused the slightly yellow solution to tum to an 
orange/brown color, gradually returning to the slightly yellow 
color in a reversible cycle. FIG. 18 is the XPS spectra showing 
changes in % transmittance ( a-e) based on the changes in the 
amount of Ce+3 and Ce+4 at pH 7.4. The control a shows 
transmittance before the addition of hydrogen peroxide; b 
shows transmittance immediately after addition of hydrogen 
peroxide; c is transmittance after 24 hours; dis transmittance 
after 3 days and e is transmittance after seven days. 
US 9,119,391 Bl 
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FIG. 17B shows that at pH 4.0 (acidic conditions), DNC 
does not exhibit a significant red shift upon addition of hydro-
gen peroxide, even though the color of the solution has turned 
slightly orange. Surprisingly, after 24 hours, the solution 
turned completely clear and a significantly large blue shift 
was observed. In FIG. 19, the control f represents transmit-
tance before the addition of hydrogen peroxide, g is transmit-
tance immediately after addition of hydrogen peroxide and h 
is the transmittance curve after 24 hours and after 3 days. 
After ten days, the solution remained clear and the addition 
of more hydrogen peroxide did not bring either the color of 
the solution back to orange or have any effect on the trans-
mittance curve. Furthermore, once the pH of dextran nanoc-
eria preparation was lowered to 4.0, the autocatalytic activity 
could not be reversed, even on raising the pH to 7.4, showing 
irreversibility at acidic pH values, such as 4.0. 
Further evidence of the nonreversibility at acidic pH is 
shown in Table 1 below. 
TABLE 1 
Total amount ofce•3 and ce•4 in DNC at different 
pH values. as determined by XPS.[a] 
H 7.4 H4 
ce+3 ce+4 ce+3 ce+4 
[%] [%] [%] [%] 
Initial 53.54 46.46 54.16 45.84 
Immediately 40.7 59.3 40.0 60.0 
after H2 0 2 addition 
10 days after H20 2 55.9 44.1 41.4 58.6 
addition 
In Table 1 above, XPS studies ofDNCatpH 7.4 and pH4.0 
revealed similar amounts of Ce+3 and Ce+4 at both pH values 
in the initial samples. Upon addition of hydrogen peroxide, a 
similar increase in the amount ofCe+4 was observed at both 
pH values. However, note that ten days after addition of 
hydrogen peroxide, DNC at pH 7.4 is able to regenerate 
returning to values for ce+3 and ce+4 similar to those in the 
initial sample, confirming the reversibility of the system at pH 
7.4. In contrast, DNC is unable to regenerate at pH 4.0, 
keeping a relatively high amount ofCe+4 after 10 days, con-
firming the nonreversibility of Ce+3 and Ce+4 values at an 
acidic pH. 
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feres with the cyclical regenerative or autocatalytic nature of 
nanoceria due to the high concentration of protons (H +) at 
low pH, and therefore inhibits the ability of nanoceria to 
scavenge more free radicals. This effect renders dextran 
nanoceria as an inefficient antioxidant at low pH. 
The observed nonreversible poisoning of dextran-coated 
nanoceria at pH 4.0 has important implications in cancer 
therapy. It is well known that most tumors have acidic 
microenvironments due to high rates of glycolysis and lactic 
10 acid production, known as the Warburg effect. Also, since the 
generation of oxygen radicals (oxidative stress) occurs in 
both tumor and healthy tissue during radiation therapy, the 
dextran coated nanoceria can faciliaite pH dependent prefer-
ential protection of healthy tissue. The cancer cells are not 
15 protected against hydrogen peroxide-induced oxidative 
stress, due to their acidic micro-environment. 
Effect ofDextran-Coated Nanoceria on Cancer Cells. 
FIGS. 20 and 21 show the effect of dextran-coated nanoc-
eria on cancer cells against hydrogen peroxide-induced tox-
20 icity. Lung cancer (A-549) cells were treated with dextran 
coated nanoceria before administering hydrogen peroxide 
(0.2M) and as shown in FIG. 20, no protection against oxi-
dative damage is observed in lung carcinoma cells. The per-
25 
30 
centage of cell viability dropped to less than 20% and is 
equivalent to the cell viability when hydrogen peroxide is 
used without DNC. 
Similar results were obtained with breast cancer (BT-474) 
cells. FIG. 21 shows that DNC provides no protection against 
oxidative damage in breast carcinoma cells; the percentage of 
cell viability is approximately 30% and is equivalent to cell 
viability when hydrogen peroxide is used to induce oxidative 
stress. 
All data points in FIGS. 20 and 21 represent the average of 
three measurements with standard errors ranging between 1.0 
35 and 2.0% which is too small to graph. 
As lung and breast tumors are among the most prevalent 
and aggressive carcinomas, requiring extensive radiation 
therapy and chemotherapy, DNC can provide long-term cyto-
protection to nontransformed surrounding cells, minimizing 
40 adverse side effects. 
Effect of Dextran Nanoceria on Other Biologically Rel-
evant Radicals. 
The overproduction of nitric oxide resulting in nitroxyl 
(NO*) radicals can lead to tissue damage during inflamma-
45 ti on associated with cardiovascular pathogenesis or heart fail-
ure. Cardiomyocytes were treated with dextran coated nano-
ceria in culture media containing 500 µM S-nitrogluathione 
(GSNO) as a nitric oxide donor. Under these conditions, NO* 
It has been proposed that the antioxidant properties of 
nanoceria are due to the presence of mixed valence states 
(Ce+3 /Ce+4 ) on the nanoparticle surface that allow for the 
scavenging of free radicals. During the scavenging process, 
Ce+3 ions are converted to Ce+4 , as shown in schematic dia- 50 
gram (3) below. 
is released from the dissociation ofGSNO in water at the rate 
of 5% per hour; therefore cells incubated with GSNO for 24 
hours were exposed to elevated levels of NO*. Results show 
(3) 
Ce3+ Oxidation - reduction cycle Ce4+ 
The system is regenerated via a series of surface chemical 
reactions between ions in solution (such as H+) and the Ce+4 
ions on the nanoparticle surface, where they are converted 
back to Ce+3 , and therefore allows for the scavenging of more 
free radicals. Theoretically, the low-pH environment inter-
that both dextran nanoceria preparations effectively protected 
cardiomyocytes against NO*-inducedoxidative stress (FIGS. 
22 and 23). This supports using dextran nanoceria to protect 
55 normal tissue from nitroxyl radical-induced damage during 
inflammation, such as in atherosclerosis and neurodegenera-
tive conditions. 
In summary, the present invention shows that biocompat-
ible dextran-coated nanoceria exhibit excellent, pH-depen-
60 dent antioxidant properties for improved cancer therapeutics, 
as DNC or ANC provide cytoprotection from free radicals to 
normal cells but not to cancer cells, which are typically in an 
acidic environment. In addition, dextran-coated nanoceria 
can be beneficial in the treatment of inflammatory diseases 
65 such as cardiovascular diseases and arthritis. 
Thus, polymer-coated nanoceria particles are provided for 
use as smart, pH-dependent therapeutic agents and devices 
US 9,119,391 Bl 
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that selectively protect healthy tissue from free radicals 
which might be elevated during chronic inflammation or dur~ 
ing radiation therapy and chemotherapy while permitting 
transformed or diseased cells in an acidic microenvironment 
to be eradicated. The selective protection of nontransformed, 
healthy cells surrounding a diseased site minimizes adverse 
side effects of aggressive therapeutic treatments, such as 
radiation therapy and chemotherapy. 
While the invention has been described, disclosed, illus-
trated and shown in various terms of certain embodiments or 10 
modifications which it has presumed in practice, the scope of 
the invention is not intended to be, nor should it be deemed to 
be, limited thereby and such other modifications or embodi-
ments as may be suggested by the teachings herein are par-
ticularly reserved especially as they fall within the breadth 15 
and scope of the claims here appended. 
We claim: 
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str~ss, radi~ti.on therapy, inflammation or chemotherapy, 
while prov1dmg no cytoprotection to said diseased cells. 
2. The process of claim 1, wherein the normal biological 
cells have a pH value between approximately 6.5 to approxi-
mately 11.0 and the diseased biological cells have a pH value 
between approximately 2.0 and approximately 6.4. 
3. The process of claim 1, wherein the plurality ofbiocom-
patible, polymer-coated cerium oxide nanoparticles are 
coated with a biodegradable polymer selected from at least 
one of a carbohydrate polymer, a synthetic pol yo I, a carboxy-
lated polymer, and derivatives thereof. 
4. The process of claim 1, wherein the polymer-coated 
cerium oxide nanoparticles are coated with a crosslinked-
aminated biodegradable polymer selected from at least one of 
a carbohydrate polymer, a synthetic polyol, a carboxylated 
polymer and derivatives thereof. 
5. The process of claim 1 wherein the normal biological 
cells include cardiomyocytes, dermal fibroblasts, lung tissue 
cells or breast tissue cells. 1. A process for protecting normal, non-transformed bio-
logical cells using a pH-dependent therapeutic agent, com-
prising: 
providing a plurality of biocompatible, polymer-coated 
cerium oxide nanoparticles having a pH-dependent anti-
oxidant property, said polymer-coated cerium oxide 
nanoparticles being an active antioxidant in pH range 
from 7 to approximately 11 while having a substantially 
reduced antioxidant activity at an acidic pH from 
approximately 2 to 6, said polymer-coated cerium oxide 
nanoparticles not able to reversibly switch from Ce3 +to 
Ce4 + at said acidic pH; and 
6. The process of claim 1, wherein the diseased biological 
20 cells include lung cancer cells, breast cancer cells, or dermal 
cancer cells. 
7. The process of claim 3, wherein the biodegradable poly-
mer is polyacrylic acid or polysaccharide. 
8. The process of claim 7, wherein the polysaccharide is 
25 dextran. 
adding an effective amount of said polymer-coated cerium 
oxide nanoparticles to a cell environment containing 
normal biological cells and diseased biological cells so 
30 
as to contact said normal biological cells and diseased 
biological cells, thereby selectively protecting said nor- 35 
ma!, non-transformed cells from hydroxyl-radical 
induced oxidative, nitroxyl-radical induced oxidative 
9. The process of claim 3, wherein a colloidal suspension 
formed by the polymer-coated cerium oxide nanoparticles is 
stable in water or phosphate buffer solution. 
10. The process of claim 4, wherein the biodegradable 
polymer is polyacrylic acid or polysaccharide. 
11. The process of claim 10, wherein the polysaccharide is 
dextran. 
12. The process of claim 4, wherein a colloidal suspension 
formed by the polymer-coated cerium oxide nanoparticles is 
stable in water or phosphate buffer solution. 
* * * * * 
